^99mTc‐Nanocolloid Bone Marrow Scintigraphy in Prostatic Cancer

Abstract

Bone marrow scintigraphy was performed in 23 patients with histologically proven carcinoma of the prostate, using a new radiopharmaceutical, Technetium-99m nanocolloid. The results suggest that although bone marrow scintigraphy is less sensitive than conventional bone scintigraphy in the detection of skeletal metastases from prostatic carcinoma, the technique may have a place in the management of patients with advanced metastatic disease, especially those who are anaemic, by identifying those patients at risk from myelosuppressive therapy.

The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer

“…Haddock et al reported nanocolloid bone marrow scintigraphy to be less sensitive than conventional bone scans for the detection of skeletal metastases from carcinoma of the prostate. 24 Bone marrow scans usually reveal cold spots (photon deficient areas due to defects in tracer accumulation) if significant marrow infiltration is present. Hot spots have also been reported due to metastatic disease, but neither metastases nor peripheral marrow expansion due to central marrow failure were seen in the three patients scanned.…”

Bone Marrow Immunoscintigraphy versus Conventional Bone Scintigraphy in the Diagnosis of Skeletal Métastasés in Urogenital Malignancies

“…Especially bone métas tasés in prostatic cancer were studied with both conven tional bone scintigraphy and nanocolloid bone marrow scintigraphy leading to equivocal results. While some studies indicated that bone marrow scintigraphy may be more specific than bone scintigraphy in detecting skeletal métastasés (81 vs. 73%) [11], sensitivity seemed to be decreased compared to conventional bone scintigraphy in patients with prostatic cancer (83 vs. 86%) [11,12], Simi lar results were obtained for different metastatic tumours including breast cancer, lung cancer and cancer of the thy roid gland, with bone marrow imaging reaching a 64-77% sensitivity in detecting métastasés of the skeleton [13][14][15], More recently, bone marrow immunoscintigraphy using anti-NCA-95 MAbs has proved to be superior to bone marrow scintigraphy using serum albumin nanocolloids in detecting bone marrow métastasés of lymphoma, breast carcinoma and small-cell bronchogenic carcinoma [2], In this study, bone scintigraphy was abnormal in 17 out of 30 patients compared to 24 patients with abnormal bone marrow scans and bone marrow immunoscans. Compared to bone marrow scans using serum albumin nanocolloids, additonal 28 marrow lesions were detected by bone marrow immunoscintigraphy; 80% of these addi tional lesions were confirmed as tumours by marrow biopsy or radiologic examinations like plain film radiog raphy, computed tomography or magnetic resonance imaging.…”

Colloid Scintigraphy Showing Red Bone Marrow Extension in Patients with Prostatic Carcinoma

“…To our knowledge only two previous studies report on bone marrow extension in patients with prostatic carcinoma. HADDOCK et al (12) described 5 patients with markedly positive bone scans, central bone marrow destruction, and red bone marrow extension. The degree of extension, however, was not reported.…”